VistaGen reported a modest revenue base for QQ1 2026 (quarter ended 2025-06-30): revenue of $244,000 with gross profit of $75,000 and a net loss of $15.1 million. The quarterly R&D spend was elevated at $11.68 million, complemented by SG&A of $4.37 million, driving an operating loss of $15.8 million and an EBITDA loss of $14.93 million. The company held $63.2 million in cash and marketable securities at quarter-end, underscoring a finite runway given the current burn profile. Management reaffirmed a clear near-term product development cadence centered on the PALISADE Phase III program for intranasal fasedienol in the acute treatment of social anxiety disorder (SAD), with topline readouts anticipated in Q4 2025 (PALISADE-3) and the first half of 2026 (PALISADE-4). In addition, VistaGen signaled ongoing IND activity (PH80 in Q4 2025) and ongoing expansion of Phase II work for other pherine programs (Itruvone and PH80). The earnings call highlighted strong open-label conversion rates (80%+ moving from randomized to open-label) and continued emphasis on nose-to-brain neurocircuitry as a differentiator in high-prevalence CNS disorders. The balance of the quarter reflects a high-octane clinical development agenda with corresponding cash burn, potential for meaningful value inflection if PALISADE data meet efficacy and safety thresholds, and notable execution risks including site performance and enrollment dynamics. Investors should monitor PALISADE topline outcomes, enrollment dynamics across PALISADE-3/4, the timing and success of the PH80 IND, and the company’s ability to extend its cash runway through financing, given the current burn trajectory.